Feb 6, 2017
Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome
Seres Therapeutics Share Key Findings From Earlier Reported SER-109 Phase 2 Clinical Study Outcome
As published in Seres Therapeutics Press Release January 31, 2017
Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome –
FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109
CAMBRIDGE, Mass.,…
View On WordPress